证券代码：002252 证券简称：上海莱士 公告编号：2025-055 上海莱士血液制品股份有限公司 2025 年第二次临时股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更、否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次会议提案涉及股东大会特别决议事项，按照《公司章程》规定，本次特 别决议事项需经出席会议股东（包括股东代理人）所持表决权 3/4 以上表决同意后方 可通过。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间为：2025 年 7 月 31 日（星期四）14:00； 网络投票时间为：2025 年 7 月 31 日（星期四）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 7 月 31 日的交易时间，即 9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2025 年 7 月 31 日 9:15 至 15:00 期间的任意时 间； 2、现场会议召开 ...

1. 经公司 2024 年第三次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 7 月 16 日刊登于巨潮资讯网及深圳证券交易所网站的《上 海莱士血液制品股份有限公司第六届董事会第十二次（临时）会议决议 的公告》； 3. 公司 2025 年 7 月 16 日刊登于巨潮资讯网及深圳证券交易所网站的《上 海莱士血液制品股份有限公司第六届监事会第七次会议决议的公告》； 公司已向本所保证，公司已向本所提供了本所为出具本法律意见书所要求 公司提供的原始书面材料、副本材料、复印材料、承诺函或证明，并无隐瞒记 载、虚假陈述和重大遗漏之处；公司提供给本所的文件和材料是真实、准确、 完整和有效的，且文件材料为副本或复印件的，其与原件一致和相符。 北京市金杜（青岛）律师事务所 关于上海莱士血液制品股份有限公司 2025 年第二次临时股东大会 之法律意见书 致：上海莱士血液制品股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受上海莱士血液制品 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《 ...

金融界消息 截至2025年7月30日收盘，上海莱士（002252）报收于6.99元，下跌0.43%，换手率0.96%， 成交量63.45万手，成交金额4.45亿元。 天眼查商业履历信息显示，上海莱士血液制品股份有限公司，成立于1988年，位于上海市，是一家以从 事医药制造业为主的企业。企业注册资本663798.4837万人民币，实缴资本663798.4837万人民币。公司 法定代表人为Jun Xu。 通过天眼查大数据分析，上海莱士血液制品股份有限公司共对外投资了25家企业，参与招投标项目690 次，知识产权方面有商标信息40条，专利信息38条，此外企业还拥有行政许可360个。 来源：金融界 资金流向方面，今日主力资金净流出3894.84万元，占比成交额8.75%。其中，超大单净流出1717.01万 元、占成交额3.86%，大单净流出2177.83万元、占成交额4.89%，中单净流出流入690.60万元、占成交 额1.55%，小单净流入3204.24万元、占成交额7.2%。 上海莱士最新一期业绩显示，截至2025一季报，公司营业总收入20.06亿元、同比减少2.45%，归属净利 润5.66亿元，同比减少25.2 ...

Core Viewpoints - The pharmaceutical and biotechnology sector is experiencing a turning point and structural market trends in the first half of 2025, with a focus on innovative drugs and their supply chain, AI healthcare, and brain-computer interfaces as structural opportunities [3][5] - The A-share pharmaceutical and biotechnology index has increased by 10.10% since the beginning of 2025, outperforming the CSI 300 index by 8.90 percentage points, ranking 4th in industry performance [3][22] - Among 480 listed pharmaceutical and biotechnology companies, 348 have seen their stock prices rise, accounting for 72.5%, with 17 stocks doubling in value [3][40] Investment Logic - The innovative drug sector is accelerating its value reconstruction through business development (BD) overseas, research and commercialization progress, and policy support. In the first half of 2025, over 50 BD transactions for innovative drugs occurred, totaling over $48 billion [5] - Significant clinical data releases and commercialization progress for major drug candidates are expected to drive stock price increases [5] - Policy initiatives, such as the March 2025 government work report emphasizing the support for innovative drugs and medical devices, are providing strong backing for the industry's long-term development [5] Market Performance - The pharmaceutical sector's valuation has seen a short-term recovery but remains at a long-term low, with a PE ratio of 29 times as of mid-2025, slightly above the 50th percentile of the past four years [3][43] - Public fund holdings in the pharmaceutical sector have increased, with the proportion of public funds in A+H shares rising to 9.05% in Q1 2025, a 0.37 percentage point increase [3][58] Sub-industry Performance - The best-performing sub-industries in the pharmaceutical sector include chemical preparations and other biological products, with increases of 25.8% and 24.0%, respectively [3][22] - The pharmaceutical industry is witnessing a structural market trend, with innovative drugs leading the charge, while traditional sectors like vaccines and traditional Chinese medicine have seen slight declines [3][29] Recommended Stocks - A robust portfolio is suggested, including companies such as Heng Rui Medicine, BeiGene, and United Imaging Healthcare, among others [10]

Production Capacity and Resource Matching - The company has six production bases located in Shanghai, Hefei, Hengyang, Zhengzhou, Wenzhou, and Nanning, with Shanghai, Hefei, and Hengyang being the largest [2] - Current production capacity matches the plasma collection volume, with ongoing expansion projects, such as the Shanghai base, designed to increase capacity to over 1,500 tons per year [2] Plasma Station and Resource Development - Prior to the acquisition of Nanyue Biological, the company had a total of 44 plasma collection stations, with Nanyue adding 9 more, distributed across 11 provinces [3] - The company focuses on both optimizing existing plasma stations and expanding new ones to ensure continuous growth in plasma collection [4] Market Conditions and Product Demand - The blood product market currently has a certain level of inventory among companies and distributors [5] - Sales of human albumin have slightly slowed due to healthcare policies and supply-demand dynamics, but there remains a rigid demand for its various medical applications [6] Pricing and Innovation - Blood product prices have experienced slight changes influenced by policy and supply-demand factors, with the company monitoring market dynamics to maintain reasonable pricing [7] - The company is committed to innovation, focusing on both "plasma expansion" and "plasma extraction," with ongoing clinical research on SR604 injection, currently in Phase IIb trials [8] Strategic Partnerships - In March 2019, the company signed an exclusive strategic cooperation agreement with Klibor, leading to collaborative efforts in quality management and product distribution, positively impacting performance [9]

General Provisions - The company aims to protect the legal rights of shareholders and creditors, and to regulate its organization and behavior according to relevant laws [3][4] - The company is established as a foreign-invested joint-stock company under Chinese law, with a registered capital of RMB 6,637,984,837 [4][5] Business Objectives and Scope - The company's business objective is to introduce advanced technology and management methods for the production and testing of blood products, aiming to enhance production capacity and quality to international standards [5][6] - The company is engaged in the production and sale of blood products, vaccines, diagnostic reagents, and testing services, with the ability to adjust its business scope as needed [6] Shares - The company's shares are issued in the form of stocks, with a total of 6,637,984,837 shares, each with a par value of RMB 1 [7] - The issuance of shares follows principles of openness, fairness, and justice, ensuring equal rights for all shareholders of the same class [7][8] Shareholder and Shareholder Meeting - The company recognizes the rights of shareholders to receive dividends, participate in meetings, supervise operations, and transfer shares [14][16] - Shareholders holding more than 10% of shares can request the convening of a temporary shareholder meeting [25][26] Board of Directors - The board of directors is responsible for the overall management of the company, including the election and remuneration of directors and supervisors [18][19] - The board must report to the shareholders on its activities and financial performance annually [69] Financial Accounting and Auditing - The company must establish a financial accounting system and conduct internal audits, with external auditors appointed by the shareholders [8] Amendments to the Articles - The articles of association can be amended by a resolution passed at a shareholder meeting [20][21]

Group 1 - The company held its sixth supervisory board meeting on July 15, 2025, with all three supervisors present [1] - The supervisory board approved the proposal to appoint Ernst & Young Hua Ming as the company's accounting firm for the fiscal year 2025, citing the firm's qualifications, independence, and capability to meet future audit needs [1] - The proposal will be submitted for review at the company's second extraordinary general meeting of shareholders in 2025 [2] Group 2 - The voting results for the proposal were unanimous, with 3 votes in favor, and no abstentions or oppositions [2] - The full announcement regarding the appointment of the accounting firm will be published in several financial newspapers and on the company's information platform for investor reference [3]

Meeting Information - The company will hold its second extraordinary general meeting of shareholders on July 31, 2025, at 14:00 [1][2] - The meeting will be conducted both in-person and via online voting platforms provided by the Shenzhen Stock Exchange [2][4] - The record date for shareholders eligible to attend the meeting is July 28, 2025, at 15:00 [2][3] Voting Procedures - Shareholders can vote through either the Shenzhen Stock Exchange trading system or the internet voting system, but must choose one method for each voting right [2][5] - The voting code for the meeting is "362252" and the voting abbreviation is "莱士投票" [4][5] - Specific procedures for online voting are detailed in the attachments provided [4][5] Attendance Requirements - Legal representatives of corporate shareholders must present identification and relevant documentation to attend the meeting [3][4] - Individual shareholders must bring their identification and shareholder account card for registration [4] - Remote shareholders can register via email or mail, with a deadline of July 30, 2025, at 16:00 [4] Proposal Details - The meeting will review non-cumulative voting proposals, with the requirement that more than 75% of the voting rights present must agree for proposals to pass [3][5] - If shareholders vote on both the total proposal and specific proposals, the first valid vote will take precedence [5]

证券代码：002252 证券简称：上海莱士 公告编号：2025-051 上海莱士血液制品股份有限公司 关于第六届董事会第十二次（临时）会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第六届董事会第十二次（临时） 会议于 2025 年 7 月 10 日以电话和邮件方式发出会议通知，并于 2025 年 7 月 15 日 14 点以现场结合通讯方式召开。 本次会议应出席董事 9 名，实际出席董事 9 名。本次会议由公司董事长谭丽 霞女士召集和主持，公司监事、高级管理人员等列席会议。会议的召集召开与表 决程序符合《公司法》和《公司章程》等有关规定。与会董事经过充分研究和讨 论，审议通过了如下议案： 1、审议通过《关于拟聘任 2025 年度会计师事务所的议案》 公司拟聘任安永华明会计师事务所（特殊普通合伙）担任公司 2025 年度会 计师事务所。 表决结果：9 票同意、0 票反对、0 票弃权。 本议案已经公司董事会审计委员会审议通过。本议案尚需提交公司 2025 年 第二次临时股东大会审议。 《关于拟聘任 2025 ...

特别提示： 证券代码：002252 证券简称：上海莱士 公告编号：2025-053 上海莱士血液制品股份有限公司 关于拟聘任2025年度会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、拟聘任会计师事务所名称：安永华明会计师事务所（特殊普通合伙） 2、上年度会计师事务所名称：毕马威华振会计师事务所（特殊普通合伙） 3、变更会计师事务所的原因：根据公司业务与未来发展的审计需求，通过 审慎研究和考量，公司拟聘任安永华明会计师事务所（特殊普通合伙）（以下简 称"安永华明"）担任公司2025年度会计师事务所。公司已就变更审计机构的相 关事宜与前、后任会计师也进行了沟通说明，前后任会计师均已知悉本事项且对 本次更换无/未提出异议。 4、本次变更会计师事务所事项符合财政部、国务院国资委、证监会印发的 《国有企业、上市公司选聘会计师事务所管理办法》（财会[2023]4号）的规定。 上海莱士血液制品股份有限公司（"公司"）于2025年7月15日召开了第六届 董事会第十二次（临时）会议及第六届监事会第七次会议，审议通过了《关于拟 聘任2025年度会计师事务 ...